Arthritis drug approved for critically ill COVID patients
Published in
2 min readJan 18, 2021
Critically ill COVID patients in the U.K. may receive an arthritis drug after a study showed that treatment lowered mortality rates and accelerated recovery times in intensive care.
The drug tocilizumab (Actemra) is an approved biologic medication for the treatment of rheumatoid arthritis. The drug works by blocking the inflammatory protein interleukin-6, or IL-6…
